ALISON SCHAEFER: Open Payments
NPI 1932198553 · FREDERICKSBURG, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,566 in 74 payments from 15 companies in 2025. Trend: 2023 $759 · 2024 $1,090 · 2025 $1,566
Food & beverage: $1,566
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 17 | $324 |
| GlaxoSmithKline, LLC. | 14 | $242 |
| Novartis Pharmaceuticals Corporation | 12 | $231 |
| Regeneron Healthcare Solutions, Inc. | 9 | $226 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $139 |
| Genentech USA, Inc. | 2 | $64 |
| CSL Behring | 2 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $59 |
| Boston Scientific Corporation | 2 | $54 |
| GENZYME CORPORATION | 2 | $53 |
Products named: DUPIXENT, FASENRA, NUCALA, NEFFY, TEZSPIRE, XOLAIR, TRELEGY ELLIPTA, Rhapsido.
Industry payments across VA — which companies pay providers there.
